Centrexion Therapeutics Appoints Dan Mendelson to its Board of Directors

“Dan is known for his astute insights on the fast-changing health policy environment,” said Sol Barer, Ph.D., chairman, Centrexion Therapeutics board of directors. “His expertise in helping business leaders in the healthcare world anticipate these changes and craft strategies to succeed in the area of biomedical innovation will bring valuable perspective to our board as we advance our mission to improve the lives of people living with chronic pain."

“At Centrexion Therapeutics, we are committed to developing new, non-opioid drugs to provide better treatments to those living with chronic pain that don't cause dependency or addiction,” said Jeffrey B. Kindler, chief executive officer of Centrexion Therapeutics. “Dan’s expertise and experience perfectly align with our mission to bridge the safety and efficacy gaps in current approaches to chronic pain management, and we are thrilled to have him join our board and support the continued growth of Centrexion.”

“Successfully addressing the opioid crisis will require the development of safe and effective pain management alternatives beyond traditional opioids,” said Mr. Mendelson. “The potential social, economic, and medical impacts of Centrexion’s innovative platform and exciting drug development efforts are significant, and I’m thrilled to be a part of it.”

Mr. Mendelson brings substantial healthcare expertise and leadership to the Centrexion board of directors. Currently, Mr. Mendelson is advisor to Avalere Health, a group which he founded in 2000 and grew organically as chief executive officer until 2015, when he sold the company to Inovalon Holdings (INOV). Prior to that, Mr. Mendelson served as associate director for health at the Office of Management and Budget where he oversaw numerous government healthcare programs and agencies, as well as the development of numerous initiatives in health information technology and medical error prevention, the electronic disease surveillance system, and policies in reimbursement and technology assessment. Mr. Mendelson presently serves on the board of Champions Oncology, as well as on the advisory boards for Faster Cures, the Alliance for Health Policy, and the Duke Margolis Center. In addition, he is a founding member of Guidon Partners, an investment management group, and is executive in residence at the Fuqua School of Business at Duke University.

Mr. Mendelson received his undergraduate degree in economics and viola performance from Oberlin College and his master’s degree in public policy from the Kennedy School of Government at Harvard University.

About Centrexion Therapeutics

Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest, exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. For more information about Centrexion Therapeutics, visit http://www.centrexion.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180815005106/en/